Energy Expenditure of People Living With HIV/AIDS
- Conditions
- HIV Lipodystrophy SyndromeHIV/AIDS
- Interventions
- Drug: use of lipid-lowering drugs.
- Registration Number
- NCT02530827
- Lead Sponsor
- University of Sao Paulo General Hospital
- Brief Summary
Background: Several studies have reported increased resting energy expenditure (REE) in people living with HIV/AIDS possibly due to changes in body composition that occurs in HIV lipodystrophy syndrome.
The aim of this study was to evaluate the influence of the use of lipid-lowering drugs in resting energy expenditure (REE) and total energy expenditure (TEE) in patients seropositive for HIV in treatment of lipodystrophy.
- Detailed Description
REE was measured by indirect calorimetry.
TEE was measured by doubly labeled water (DLW) technique and an activity monitor based on accelerometry (AM).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 45
- Use of antiretroviral therapy for at least 4 months
- A cluster of differentiation 4 (CD4) T-cell count of >200 cells/mm3
- Use of lipid-lowering drugs for at least 1 month (group HIV-seropositive with lipodystrophy and use of lipid-lowering)
- Signs or symptoms of opportunistic infections
- Thyroid disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description LIPO+HIPO+ use of lipid-lowering drugs. HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.
- Primary Outcome Measures
Name Time Method Total Energy Expenditure (kcal/d) 14 day Resting Energy Expenditure (kcal/d) 1 day
- Secondary Outcome Measures
Name Time Method Correlation between doubly labeled water and accelerometer to measure total energy expenditure (ICC, 95% CI) 14 days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.